BIOMAT Database Logo BIOMAT Database Logo

Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. 2002

Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
College of Pharmacy, University of New Mexico, Albuquerque, NM, USA.

This retrospective cohort study revealed that linezolid resistance in vancomycin-resistant Enterococcus faecium was dependent on prior linezolid exposure and duration of linezolid therapy. These strains of E. faecium were resistant to the entire class of oxazolidinones.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069349 Linezolid An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract. Linezolide,N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide,PNU-100766,U 100766,U-100766,Zyvox,100766, U,PNU 100766,PNU100766,U100766
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D016908 Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method. Bacterial Infections, Gram-Positive,Infections, Gram-Positive Bacterial,Bacterial Infection, Gram-Positive,Bacterial Infections, Gram Positive,Gram Positive Bacterial Infections,Gram-Positive Bacterial Infection,Infection, Gram-Positive Bacterial,Infections, Gram Positive Bacterial

Related Publications

Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.
May 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid.
June 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.
March 2002, The New England journal of medicine,
Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis.
August 2002, The Pediatric infectious disease journal,
Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Vancomycin-resistant Enterococcus faecium meningitis successfully treated with linezolid.
May 2008, Southern medical journal,
Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium.
June 2018, Diagnostic microbiology and infectious disease,
Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption.
February 2021, International journal of medical microbiology : IJMM,
Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization.
August 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.
February 2001, Antimicrobial agents and chemotherapy,
Manjunath P Pai, and Keith A Rodvold, and Paul C Schreckenberger, and Ronald D Gonzales, and Jennifer M Petrolatti, and John P Quinn
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
April 2001, Lancet (London, England),
Copied contents to your clipboard!